Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.
https://adverum.com/© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd diberi kuasa dan dikawal selia oleh Suruhanjaya Sekuriti dan Bursa Cyprus mengikut lesen No.281/15 yang dikeluarkan pada 25/09/2015. Tanda dagangan "Just2Trade" dimiliki oleh LimeTrading (CY) Ltd.
Nombor Pendaftaran: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Penafian:
Semua promosi, bahan dan maklumat laman web ini mungkin telah dikenakan syarat.
Sila hubungi syarikat untuk maklumat lanjut.
Dagangan di pasaran kewangan membawa risiko.Nilai pelaburan boleh meningkat dan menurun dan pelabur mungkin kehilangan semua modal pelaburan mereka.Dalam kes produk yang dimanfaatkan, kerugian mungkin lebih daripada modal awal yang dilaburkan. Maklumat terperinci mengenai risiko yang berkaitan dengan perdagangan di pasaran kewangan boleh didapati dalam pendedahan risiko penuh.
E-mail: 24_support@just2trade.online
